The study looks at whether a specific protein in the blood, called apolipoprotein, can predict how much weight a person might lose after sleeve gastrectomy, a surgery for people with severe obesity. We want to find a specific level of this protein that shows which patients are most likely to lose weight successfully after surgery. By identifying this level, we hope to guide doctors in deciding who should have the surgery and who might do better with non-surgical weight loss methods.

The subject of our research is whether serum apolipoprotein levels can be a predictive value for weight loss in patients who will undergo sleeve gastrectomy due to morbid obesity. Our aim is to determine a cut-off value for patients who benefit most from bariatric surgery based on preoperative serum apolipoprotein levels. By including this value among the surgical indications, we plan to direct patients less likely to benefit from surgery to conservative approaches.

Inclusion Criteria:

• Patients aged 18 to 75
• International Classification of Diseases (ICD) code E66 diagnosis (obesity)
• Patients who have given consent for sleeve gastrectomy
• Patients who are suitable for general anesthesia

Exclusion Criteria:

• Patients who did not give consent to be included in the study
• Patients who are scheduled for surgery other than sleeve gastrectomy

Patients applying to Başakşehir Çam Sakura City Hospital General Surgery Clinic for bariatric surgery